Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
BriaCell Therapeutics ( (TSE:BCT) ) has issued an announcement.
BriaCell Therapeutics announced a share consolidation plan, converting every ten pre-consolidation common shares into one post-consolidation share, to comply with Nasdaq listing requirements. The consolidation, pending approval from the TSX and Nasdaq, is set to be effective on August 25, 2025, with the adjusted shares continuing to trade under existing symbols, ensuring streamlined operations and market compliance.
The most recent analyst rating on (TSE:BCT) stock is a Buy with a C$32.00 price target. To see the full list of analyst forecasts on BriaCell Therapeutics stock, see the TSE:BCT Stock Forecast page.
Spark’s Take on TSE:BCT Stock
According to Spark, TipRanks’ AI Analyst, TSE:BCT is a Neutral.
BriaCell Therapeutics has a challenging financial position with no revenue and consistent losses, heavily impacting its stock score. Despite this, recent corporate developments in cancer treatment provide some potential upside. Technical indicators are mixed, and valuation concerns persist with a negative P/E ratio. The company’s reliance on external financing is a notable risk.
To see Spark’s full report on TSE:BCT stock, click here.
More about BriaCell Therapeutics
BriaCell Therapeutics Corp. is a clinical-stage biotechnology company focused on developing novel immunotherapies to transform cancer care.
Average Trading Volume: 29,547
Technical Sentiment Signal: Sell
Current Market Cap: C$17.55M
Find detailed analytics on BCT stock on TipRanks’ Stock Analysis page.